170 related articles for article (PubMed ID: 34627720)
1. Using molecular testing to improve the management of thyroid nodules with indeterminate cytology: an institutional experience with review of molecular alterations.
Glass RE; Marotti JD; Kerr DA; Levy JJ; Vaickus LJ; Gutmann EJ; Tafe LJ; Motanagh SA; Sorensen MJ; Davies L; Liu X
J Am Soc Cytopathol; 2022; 11(2):79-86. PubMed ID: 34627720
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
[TBL] [Abstract][Full Text] [Related]
3. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
4. ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule.
Fazeli SR; Zehr B; Amraei R; Toraldo G; Guan H; Kindelberger D; Lee S; Cerda S
Thyroid; 2020 Oct; 30(10):1528-1534. PubMed ID: 32349630
[No Abstract] [Full Text] [Related]
5. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
6. Benign call rate and molecular test result distribution of ThyroSeq v3.
Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
[TBL] [Abstract][Full Text] [Related]
7. Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: A comparison of two proprietary testing platforms.
Partyka KL; Randolph ML; Lawrence KA; Cramer H; Wu HH
Diagn Cytopathol; 2018 Apr; 46(4):320-325. PubMed ID: 29446257
[TBL] [Abstract][Full Text] [Related]
8. Performance of repeat cytology with reflex ThyroSeq genomic classifier for indeterminant thyroid cytology.
O'Conor CJ; Dash RC; Jones CK; Jiang XS
Cancer Cytopathol; 2022 Jun; 130(6):469-476. PubMed ID: 35045202
[TBL] [Abstract][Full Text] [Related]
9. Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology.
Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
Thyroid; 2015 Nov; 25(11):1217-23. PubMed ID: 26356635
[TBL] [Abstract][Full Text] [Related]
10. Chronic Lymphocytic Thyroiditis May Limit the Utility of Molecular Testing in AUS/FLUS Thyroid Nodules.
Remer LF; Linhares SM; Scola WH; Lew JI
J Surg Res; 2023 Sep; 289():229-233. PubMed ID: 37148856
[TBL] [Abstract][Full Text] [Related]
11. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
[TBL] [Abstract][Full Text] [Related]
12. Atypia of undetermined significance in thyroid cytology: Nuclear atypia and architectural atypia are associated with different molecular alterations and risks of malignancy.
Glass RE; Levy JJ; Motanagh SA; Vaickus LJ; Liu X
Cancer Cytopathol; 2021 Dec; 129(12):966-972. PubMed ID: 34399035
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of molecular testing in cytologically indeterminate thyroid nodules with histologic correlation: Experience at a heterogenous multihospital system.
Sura GH; Thrall MJ; Rogers J; Hodjat P; Christensen P; Cubb TD; Khadra HS; Thomas JS; Jacobi EM
Diagn Cytopathol; 2024 Feb; 52(2):82-92. PubMed ID: 37950548
[TBL] [Abstract][Full Text] [Related]
14. Role of Ancillary Techniques in Thyroid Cytology Specimens.
Nishino M; Krane JF
Acta Cytol; 2020; 64(1-2):40-51. PubMed ID: 30947167
[TBL] [Abstract][Full Text] [Related]
15. Probability of malignancy as determined by ThyroSeq v3 genomic classifier varies according to the subtype of atypia.
Gajzer DC; Tjendra Y; Kerr DA; Algashaamy K; Zuo Y; Menendez SG; Jorda M; Garcia-Buitrago M; Gomez-Fernandez C; Velez Torres JM
Cancer Cytopathol; 2022 Nov; 130(11):881-890. PubMed ID: 35775861
[TBL] [Abstract][Full Text] [Related]
16. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
[TBL] [Abstract][Full Text] [Related]
17. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
Selvaggi SM
Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719
[TBL] [Abstract][Full Text] [Related]
18. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
19. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
[TBL] [Abstract][Full Text] [Related]
20. Qualifiers of atypia in the cytologic diagnosis of thyroid nodules are associated with different Afirma gene expression classifier results and clinical outcomes.
Baca SC; Wong KS; Strickland KC; Heller HT; Kim MI; Barletta JA; Cibas ES; Krane JF; Marqusee E; Angell TE
Cancer Cytopathol; 2017 May; 125(5):313-322. PubMed ID: 28152275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
